cbd nagoya 2021December 15, 2021
COP 15 was originally expected to convene in October 2020 in Kunming, China. Due to the global pandemic emerging in early 2020, the meetings were rescheduled several times. On 18 August 2021, the Secretariat announced that COP 15 will not take place in person in October 2021. Instead, COP 15 will take place in two parts.
The in-person event in 2022 will address the remaining agenda items of the Meetings, including the finalization and adoption of the post-2020 global biodiversity framework. A high-level segment is expected to take place during this event as well.
Several meetings announced in the CBD’s revised schedule will provide for in-person preparatory negotiations on the post-2020 global biodiversity framework and other substantive matters. These meetings are: the resumed session of SBSTTA 24; the resumed session of SBI 3; and the Open-Ended Working Group on the Post-2020 Global Biodiversity Framework. These are tentatively expected to convene in person in Geneva, Switzerland, in January 2022.
The first part will take place in a virtual format, from 11-15 October 2021. Accredited delegates from embassies and organizations already located and based in China may gather in Kunming during this period. The second part of COP 15 will be a face-to-face meeting in Kunming, China, from 25 April-8 May 2022.
COP 15 will now take place in two parts: a virtual format from 11-15 October 2021, and an in-person event from 25 April-8 May 2022.
The Secretariat of the Convention on Biological Diversity (CBD) has announced a revised schedule for the 15th meeting of the Conference of the Parties (COP 15), the tenth meeting of the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on Biosafety (CP-MOP 10), and the fourth meeting of the Conference of the Parties serving as the meeting of the Parties to the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization (NP-MOP 4). COP 15 is expected to provide for the conclusion of negotiations on a post-2020 global biodiversity framework.
Among the agenda items for COP 15 is the conclusion of negotiations on a post-2020 global biodiversity framework.
SBSTTA 24 and SBI 3 held on-line meetings in May-June 2021. An online session of the Open-ended Working Group on the Post-2020 Global Biodiversity Framework will take place from 23 August-3 September 2021.
The October 2021 event will include an opening of the meetings, discussion of agenda items that must be addressed for the continuation of the operations of the Convention and the Protocols, and a high-level segment. China, in consultation with the Secretariat, will convene the virtual high-level segment from 12-13 October 2021, with the objective of providing political momentum for the preparations of the post-2020 global biodiversity framework.
Registration for the first part of COP 15 is open until 1 October 2021. [CBD Announcement]
On 18 to 26 January 2021 the Executive Board of the World Health Organization will meet. One important agenda item 14.4 will consider a report prepared by the WHO Director-General on the public health implications of implementation of the Nagoya Protocol (document EB 148/21). The Nagoya Protocol deals with access and benefit sharing, including in relation to pathogens.
TWN calls for the way forward to be a Member-State process and not a Secretariat-driven one.
One item of note with respect to the Secretariat�s work is how Member States will be involved in the development of the �bio-bank� for pathogens that has been proposed by the WHO DG. While this work is of relevance to the Nagoya Protocol and public health, many unanswered questions exist about it. Member States should take care to not accidentally endorse continued development of the �bio-bank� without new information on the plan and establishment of a clear guiding role of Member States in its possible creation. Consistency with the rights of Member States under the CBD and Nagoya Protocol also needs to be ensured. Questions related to the bio-bank have been elaborated in more detail in an earlier TWN paper.
As COVID-19 vaccines are approved and rolled out, the issue of timely access to the vaccines in developing and least developed countries has become even more urgent. The current continuing reliance on a handful of pharmaceutical companies with limited production capacity coupled with the buying up of most of the available vaccines by several developed countries is unacceptable.
TWN Info Service on Biodiversity and Traditional Knowledge (Jan21/03) 17 January 2021 Third World Network.
Dear Friends and Colleagues,
Third World Network has prepared comments on several key aspects of the WHO report, and we are concerned over the flawed methodology of a survey that was done by the WHO Secretariat, and the unbalanced (even misleading) nature of the report. The report concludes by recommending that the Executive Board take no major action and instead requests the Secretariat to continue its work. Such a broad recommendation pre-empts a proper discussion by WHO Member States that should first focus on more clarity and understanding of the facts and issues, especially fair and equitable benefit sharing for public health objectives.
The coming week�s Executive Board meeting is expected to adopt a recommendation on the item 14.4 to the World Health Assembly, which is to convene in May.